Avantor (NYSE:AVTR) Director Simon Dingemans Acquires 25,000 Shares

Avantor, Inc. (NYSE:AVTR) Director Simon Dingemans purchased 25,000 shares of Avantor stock in a transaction dated Friday, May 1st. The stock was bought at an average price of $8.14 per share, with a total value of $203,500.00. Following the acquisition, the director directly owned 25,000 shares of the company’s stock, valued at approximately $203,500. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Avantor Stock Up 0.7%

Shares of Avantor stock traded up $0.06 on Tuesday, hitting $8.05. The company had a trading volume of 5,450,070 shares, compared to its average volume of 10,958,086. The firm has a market capitalization of $5.49 billion, a P/E ratio of -9.93, a P/E/G ratio of 4.65 and a beta of 0.94. Avantor, Inc. has a twelve month low of $7.26 and a twelve month high of $15.93. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.17. The stock has a 50-day moving average of $8.14 and a 200-day moving average of $10.45.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.01. Avantor had a positive return on equity of 9.95% and a negative net margin of 8.42%.The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same period in the previous year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up .0% compared to the same quarter last year. Research analysts predict that Avantor, Inc. will post 0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Jefferies Financial Group restated an “underperform” rating and issued a $8.00 price objective on shares of Avantor in a report on Thursday, February 12th. Evercore set a $10.00 price objective on Avantor in a report on Wednesday, February 11th. UBS Group reissued a “neutral” rating and issued a $10.50 price objective on shares of Avantor in a report on Thursday, February 12th. Zacks Research raised Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Stifel Nicolaus set a $10.00 price objective on Avantor in a report on Thursday, February 12th. Three research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $11.39.

Institutional Investors Weigh In On Avantor

A number of institutional investors and hedge funds have recently modified their holdings of AVTR. EverSource Wealth Advisors LLC raised its holdings in shares of Avantor by 119.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock valued at $29,000 after purchasing an additional 1,189 shares during the period. Private Trust Co. NA increased its holdings in shares of Avantor by 46.2% during the 4th quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock worth $32,000 after acquiring an additional 875 shares during the last quarter. Strategic Wealth Investment Group LLC acquired a new position in shares of Avantor during the 2nd quarter worth approximately $32,000. Los Angeles Capital Management LLC acquired a new position in shares of Avantor during the 4th quarter worth approximately $32,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after acquiring an additional 1,064 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.